 | • レポートコード：GIR-2104Z07653 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、インフリキシマブ＆バイオシミラーのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。インフリキシマブ＆バイオシミラーの種類別市場規模（インフリキシマブ、インフリキシマブ-dyyb、インフリキシマブ-アブダ）、用途別市場規模（クローン病、小児クローン病、潰瘍性大腸炎、関節リウマチ、強直性脊椎炎、乾癬性関節炎、尋常性乾癬）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・インフリキシマブ＆バイオシミラーの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Janssen Biotech、Merck and Co.、Pfizer ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：インフリキシマブ、インフリキシマブ-dyyb、インフリキシマブ-アブダ ・用途別分析2016年-2026年：クローン病、小児クローン病、潰瘍性大腸炎、関節リウマチ、強直性脊椎炎、乾癬性関節炎、尋常性乾癬 ・インフリキシマブ＆バイオシミラーの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・インフリキシマブ＆バイオシミラーのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・インフリキシマブ＆バイオシミラーのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・インフリキシマブ＆バイオシミラーの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・インフリキシマブ＆バイオシミラーの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Infliximab and Biosimilar market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Infliximab and Biosimilar size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Infliximab and Biosimilar market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Infliximab and Biosimilar market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Infliximab
Infliximab-dyyb
Infliximab-abda
Market segment by Application can be divided into
Crohn’s Disease
Pediatric Crohn’s Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
The key market players for global Infliximab and Biosimilar market are listed below:
Janssen Biotech
Merck and Co.
Pfizer
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Infliximab and Biosimilar Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Infliximab and Biosimilar Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Infliximab
1.2.3 Infliximab-dyyb
1.2.4 Infliximab-abda
1.3 Market Analysis by Application
1.3.1 Overview: Global Infliximab and Biosimilar Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Crohn’s Disease
1.3.3 Pediatric Crohn’s Disease
1.3.4 Ulcerative Colitis
1.3.5 Rheumatoid Arthritis
1.3.6 Ankylosing Spondylitis
1.3.7 Psoriatic Arthritis
1.3.8 Plaque Psoriasis
1.4 Global Infliximab and Biosimilar Market Size & Forecast
1.4.1 Global Infliximab and Biosimilar Sales in Value (2016-2026))
1.4.2 Global Infliximab and Biosimilar Sales in Volume (2016-2026)
1.4.3 Global Infliximab and Biosimilar Price by Type (2016-2026) & (USD/Unit)
1.5 Global Infliximab and Biosimilar Production Capacity Analysis
1.5.1 Global Infliximab and Biosimilar Total Production Capacity (2016-2026)
1.5.2 Global Infliximab and Biosimilar Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Infliximab and Biosimilar Market Drivers
1.6.2 Infliximab and Biosimilar Market Restraints
1.6.3 Infliximab and Biosimilar Trends Analysis
2 Manufacturers Profiles
2.1 Janssen Biotech
2.1.1 Janssen Biotech Details
2.1.2 Janssen Biotech Major Business
2.1.3 Janssen Biotech Infliximab and Biosimilar Product and Services
2.1.4 Janssen Biotech Infliximab and Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Merck and Co.
2.2.1 Merck and Co. Details
2.2.2 Merck and Co. Major Business
2.2.3 Merck and Co. Infliximab and Biosimilar Product and Services
2.2.4 Merck and Co. Infliximab and Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Infliximab and Biosimilar Product and Services
2.3.4 Pfizer Infliximab and Biosimilar Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Infliximab and Biosimilar Sales by Manufacturer
3.1 Global Infliximab and Biosimilar Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Infliximab and Biosimilar Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Infliximab and Biosimilar
3.4 Market Concentration Rate
3.4.1 Top 3 Infliximab and Biosimilar Manufacturer Market Share
3.4.2 Top 6 Infliximab and Biosimilar Manufacturer Market Share
3.5 Global Infliximab and Biosimilar Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Infliximab and Biosimilar Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Infliximab and Biosimilar Market Size by Region
4.1.1 Global Infliximab and Biosimilar Sales in Volume by Region (2016-2026)
4.1.2 Global Infliximab and Biosimilar Revenue by Region (2016-2026)
4.2 North America Infliximab and Biosimilar Revenue (2016-2026)
4.3 Europe Infliximab and Biosimilar Revenue (2016-2026)
4.4 Asia-Pacific Infliximab and Biosimilar Revenue (2016-2026)
4.5 South America Infliximab and Biosimilar Revenue (2016-2026)
4.6 Middle East and Africa Infliximab and Biosimilar Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Infliximab and Biosimilar Sales in Volume by Type (2016-2026)
5.2 Global Infliximab and Biosimilar Revenue by Type (2016-2026)
5.3 Global Infliximab and Biosimilar Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Infliximab and Biosimilar Sales in Volume by Application (2016-2026)
6.2 Global Infliximab and Biosimilar Revenue by Application (2016-2026)
6.3 Global Infliximab and Biosimilar Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Infliximab and Biosimilar Sales by Type (2016-2026)
7.2 North America Infliximab and Biosimilar Sales by Application (2016-2026)
7.3 North America Infliximab and Biosimilar Market Size by Country
7.3.1 North America Infliximab and Biosimilar Sales in Volume by Country (2016-2026)
7.3.2 North America Infliximab and Biosimilar Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Infliximab and Biosimilar Sales by Type (2016-2026)
8.2 Europe Infliximab and Biosimilar Sales by Application (2016-2026)
8.3 Europe Infliximab and Biosimilar Market Size by Country
8.3.1 Europe Infliximab and Biosimilar Sales in Volume by Country (2016-2026)
8.3.2 Europe Infliximab and Biosimilar Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Infliximab and Biosimilar Sales by Type (2016-2026)
9.2 Asia-Pacific Infliximab and Biosimilar Sales by Application (2016-2026)
9.3 Asia-Pacific Infliximab and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Infliximab and Biosimilar Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Infliximab and Biosimilar Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Infliximab and Biosimilar Sales by Type (2016-2026)
10.2 South America Infliximab and Biosimilar Sales by Application (2016-2026)
10.3 South America Infliximab and Biosimilar Market Size by Country
10.3.1 South America Infliximab and Biosimilar Sales in Volume by Country (2016-2026)
10.3.2 South America Infliximab and Biosimilar Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Infliximab and Biosimilar Sales by Type (2016-2026)
11.2 Middle East & Africa Infliximab and Biosimilar Sales by Application (2016-2026)
11.3 Middle East & Africa Infliximab and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Infliximab and Biosimilar Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Infliximab and Biosimilar Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Infliximab and Biosimilar Typical Distributors
12.3 Infliximab and Biosimilar Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Infliximab and Biosimilar Revenue by Type, (USD Million), 2021-2026
Table 2. Global Infliximab and Biosimilar Revenue by Application, (USD Million), 2021-2026
Table 3. Janssen Biotech Basic Information, Manufacturing Base and Competitors
Table 4. Janssen Biotech Major Business
Table 5. Janssen Biotech Infliximab and Biosimilar Product and Services
Table 6. Janssen Biotech Infliximab and Biosimilar Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Merck and Co. Basic Information, Manufacturing Base and Competitors
Table 8. Merck and Co. Major Business
Table 9. Merck and Co. Infliximab and Biosimilar Product and Services
Table 10. Merck and Co. Infliximab and Biosimilar Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Pfizer Basic Information, Manufacturing Base and Competitors
Table 12. Pfizer Major Business
Table 13. Pfizer Infliximab and Biosimilar Product and Services
Table 14. Pfizer Infliximab and Biosimilar Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Global Infliximab and Biosimilar Sales by Manufacturer (2019-2021e) & (K Units)
Table 16. Global Infliximab and Biosimilar Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 17. Market Position of Manufacturers in Infliximab and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 18. Global Infliximab and Biosimilar Production Capacity by Company, (K Units): 2020 VS 2021
Table 19. Head Office and Infliximab and Biosimilar Production Site of Key Manufacturer
Table 20. Global Infliximab and Biosimilar Sales by Region (2016-2021e) & (K Units)
Table 21. Global Infliximab and Biosimilar Sales by Region (2021-2026) & (K Units)
Table 22. Global Infliximab and Biosimilar Revenue by Region (2016-2021e) & (USD Million)
Table 23. Global Infliximab and Biosimilar Revenue by Region (2021-2026) & (USD Million)
Table 24. Global Infliximab and Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 25. Global Infliximab and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 26. Global Infliximab and Biosimilar Revenue by Type (2016-2021e) & (USD Million)
Table 27. Global Infliximab and Biosimilar Revenue by Type (2021-2026) & (USD Million)
Table 28. Global Infliximab and Biosimilar Price by Type (2016-2021e) & (USD/Unit)
Table 29. Global Infliximab and Biosimilar Price by Type (2021-2026) & (USD/Unit)
Table 30. Global Infliximab and Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 31. Global Infliximab and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 32. Global Infliximab and Biosimilar Revenue by Application (2016-2021e) & (USD Million)
Table 33. Global Infliximab and Biosimilar Revenue by Application (2021-2026) & (USD Million)
Table 34. Global Infliximab and Biosimilar Price by Application (2016-2021e) & (USD/Unit)
Table 35. Global Infliximab and Biosimilar Price by Application (2021-2026) & (USD/Unit)
Table 36. North America Infliximab and Biosimilar Sales by Country (2016-2021e) & (K Units)
Table 37. North America Infliximab and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 38. North America Infliximab and Biosimilar Revenue by Country (2016-2021e) & (USD Million)
Table 39. North America Infliximab and Biosimilar Revenue by Country (2021-2026) & (USD Million)
Table 40. North America Infliximab and Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 41. North America Infliximab and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 42. North America Infliximab and Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 43. North America Infliximab and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 44. Europe Infliximab and Biosimilar Sales by Country (2016-2021e) & (K Units)
Table 45. Europe Infliximab and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 46. Europe Infliximab and Biosimilar Revenue by Country (2016-2021e) & (USD Million)
Table 47. Europe Infliximab and Biosimilar Revenue by Country (2021-2026) & (USD Million)
Table 48. Europe Infliximab and Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 49. Europe Infliximab and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 50. Europe Infliximab and Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 51. Europe Infliximab and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 52. Asia-Pacific Infliximab and Biosimilar Sales by Region (2016-2021e) & (K Units)
Table 53. Asia-Pacific Infliximab and Biosimilar Sales by Region (2021-2026) & (K Units)
Table 54. Asia-Pacific Infliximab and Biosimilar Revenue by Region (2016-2021e) & (USD Million)
Table 55. Asia-Pacific Infliximab and Biosimilar Revenue by Region (2021-2026) & (USD Million)
Table 56. Asia-Pacific Infliximab and Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 57. Asia-Pacific Infliximab and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 58. Asia-Pacific Infliximab and Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 59. Asia-Pacific Infliximab and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 60. South America Infliximab and Biosimilar Sales by Country (2016-2021e) & (K Units)
Table 61. South America Infliximab and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 62. South America Infliximab and Biosimilar Revenue by Country (2016-2021e) & (USD Million)
Table 63. South America Infliximab and Biosimilar Revenue by Country (2021-2026) & (USD Million)
Table 64. South America Infliximab and Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 65. South America Infliximab and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 66. South America Infliximab and Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 67. South America Infliximab and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 68. Middle East & Africa Infliximab and Biosimilar Sales by Country (2016-2021e) & (K Units)
Table 69. Middle East & Africa Infliximab and Biosimilar Sales by Country (2021-2026) & (K Units)
Table 70. Middle East & Africa Infliximab and Biosimilar Revenue by Country (2016-2021e) & (USD Million)
Table 71. Middle East & Africa Infliximab and Biosimilar Revenue by Country (2021-2026) & (USD Million)
Table 72. Middle East & Africa Infliximab and Biosimilar Sales by Type (2016-2021e) & (K Units)
Table 73. Middle East & Africa Infliximab and Biosimilar Sales by Type (2021-2026) & (K Units)
Table 74. Middle East & Africa Infliximab and Biosimilar Sales by Application (2016-2021e) & (K Units)
Table 75. Middle East & Africa Infliximab and Biosimilar Sales by Application (2021-2026) & (K Units)
Table 76. Direct Channel Pros & Cons
Table 77. Indirect Channel Pros & Cons
Table 78. Infliximab and Biosimilar Typical Distributors
Table 79. Infliximab and Biosimilar Typical Customers
List of Figures
Figure 1. Infliximab and Biosimilar Picture
Figure 2. Global Infliximab and Biosimilar Sales Market Share by Type in 2020
Figure 3. Infliximab
Figure 4. Infliximab-dyyb
Figure 5. Infliximab-abda
Figure 6. Global Infliximab and Biosimilar Sales Market Share by Application in 2020
Figure 7. Crohn's Disease
Figure 8. Pediatric Crohn's Disease
Figure 9. Ulcerative Colitis
Figure 10. Rheumatoid Arthritis
Figure 11. Ankylosing Spondylitis
Figure 12. Psoriatic Arthritis
Figure 13. Plaque Psoriasis
Figure 14. Global Infliximab and Biosimilar Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 15. Global Infliximab and Biosimilar Market Size and Forecast (2016-2026) & (USD Million)
Figure 16. United States Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. Canada Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Mexico Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Germany Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. France Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. United Kingdom Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Russia Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Italy Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. China Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Japan Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Korea Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. India Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Southeast Asia Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Australia Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Brazil Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Egypt Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Saudi Arabia Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 33. South Africa Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 34. Turkey Infliximab and Biosimilar Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 35. Global Infliximab and Biosimilar Sales (2016-2026) & (K Units)
Figure 36. Global Infliximab and Biosimilar Production Capacity (2016-2026) & (K Units)
Figure 37. Global Infliximab and Biosimilar Production Capacity by Geographic Region: 2020 VS 2021
Figure 38. Infliximab and Biosimilar Market Drivers
Figure 39. Infliximab and Biosimilar Market Restraints
Figure 40. Infliximab and Biosimilar Market Trends
Figure 41. Global Infliximab and Biosimilar Sales Market Share by Manufacturer in 2020
Figure 42. Global Infliximab and Biosimilar Revenue Market Share by Manufacturer in 2020
Figure 43. Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 44. Top 3 Infliximab and Biosimilar Manufacturer (Revenue) Market Share in 2020
Figure 45. Top 6 Infliximab and Biosimilar Manufacturer (Revenue) Market Share in 2020
Figure 46. Global Infliximab and Biosimilar Sales Market Share by Region (2016-2026)
Figure 47. Global Infliximab and Biosimilar Revenue Market Share by Region (2016-2026)
Figure 48. North America Infliximab and Biosimilar Revenue (2016-2026) & (USD Million)
Figure 49. Europe Infliximab and Biosimilar Revenue (2016-2026) & (USD Million)
Figure 50. Asia-Pacific Infliximab and Biosimilar Revenue (2016-2026) & (USD Million)
Figure 51. South America Infliximab and Biosimilar Revenue (2016-2026) & (USD Million)
Figure 52. Middle East & Africa Infliximab and Biosimilar Revenue (2016-2026) & (USD Million)
Figure 53. Global Infliximab and Biosimilar Sales Market Share by Type (2016-2026)
Figure 54. Global Infliximab and Biosimilar Revenue Market Share by Type (2016-2026)
Figure 55. Global Infliximab and Biosimilar Price by Type (2016-2026) & (USD/Unit)
Figure 56. Global Infliximab and Biosimilar Sales Market Share by Application (2016-2026)
Figure 57. Global Infliximab and Biosimilar Revenue Market Share by Application (2016-2026)
Figure 58. Global Infliximab and Biosimilar Price by Application (2016-2026) & (USD/Unit)
Figure 59. North America Infliximab and Biosimilar Sales Market Share by Country (2016-2026)
Figure 60. North America Infliximab and Biosimilar Revenue Market Share by Country (2016-2026)
Figure 61. North America Infliximab and Biosimilar Sales Market Share by Type (2016-2026)
Figure 62. North America Infliximab and Biosimilar Sales Market Share by Application (2016-2026)
Figure 63. Europe Infliximab and Biosimilar Sales Market Share by Country (2016-2026)
Figure 64. Europe Infliximab and Biosimilar Revenue Market Share by Country (2016-2026)
Figure 65. Europe Infliximab and Biosimilar Sales Market Share by Type (2016-2026)
Figure 66. Europe Infliximab and Biosimilar Sales Market Share by Application (2016-2026)
Figure 67. Asia-Pacific Infliximab and Biosimilar Sales Market Share by Region (2016-2026)
Figure 68. Asia-Pacific Infliximab and Biosimilar Revenue Market Share by Region (2016-2026)
Figure 69. Asia-Pacific Infliximab and Biosimilar Sales Market Share by Region (2016-2026)
Figure 70. Asia-Pacific Infliximab and Biosimilar Sales Market Share by Application (2016-2026)
Figure 71. South America Infliximab and Biosimilar Sales Market Share by Country (2016-2026)
Figure 72. South America Infliximab and Biosimilar Revenue Market Share by Country (2016-2026)
Figure 73. South America Infliximab and Biosimilar Sales Market Share by Type (2016-2026)
Figure 74. South America Infliximab and Biosimilar Sales Market Share by Application (2016-2026)
Figure 75. Middle East & Africa Infliximab and Biosimilar Sales Market Share by Country (2016-2026)
Figure 76. Middle East & Africa Infliximab and Biosimilar Revenue Market Share by Country (2016-2026)
Figure 77. Middle East & Africa Infliximab and Biosimilar Sales Market Share by Type (2016-2026)
Figure 78. Middle East & Africa Infliximab and Biosimilar Sales Market Share by Application (2016-2026)
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source
世界のベーチェット病治療市場規模・現状・予測（2021年-2027年） Behcet disease, also called Behcet's syndrome, is a rare disorder that causes blood vessel inflammation throughout your body. Market Analysis and Insights: Global Behcet Disease Treatment Market The global Behcet Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX…- 世界のクローン病市場規模・現状・予測（2021年-2027年） Crohn’s disease refers to long term inflammatory bowel disease, which causes inflammation of the lining of the digestive tract. It affects the large and small intestine and is generally diagnosed in persons within the age group of 20-29. It can have severe or acute outcomes. Signs and symptoms of Cr…
- 世界のクローン病診断・治療市場規模・現状・予測（2021年-2027年） Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals. Market Analysis and Insights: Global Crohn…
- 世界のクローン病診断・治療市場規模・現状・予測（2021年-2027年） Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals. Market Analysis and Insights: Global Crohn…
- 世界のクローン病診断・治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Crohn's Disease Diagnostic and Therapeutic Market The global Crohn's Disease Diagnostic and Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in an…